{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T11:22:39Z","timestamp":1774437759339,"version":"3.50.1"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2014,11,11]],"date-time":"2014-11-11T00:00:00Z","timestamp":1415664000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0112188","type":"journal-article","created":{"date-parts":[[2014,11,11]],"date-time":"2014-11-11T18:58:35Z","timestamp":1415732315000},"page":"e112188","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":33,"title":["Mosaicism of Podocyte Involvement Is Related to Podocyte Injury in Females with Fabry Disease"],"prefix":"10.1371","volume":"9","author":[{"given":"Michael","family":"Mauer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Glynn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Einar","family":"Svarstad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilla","family":"T\u00f8ndel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Claire","family":"Gubler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"West","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexey","family":"Sokolovskiy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chester","family":"Whitley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Behzad","family":"Najafian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2014,11,11]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(08)61589-5","article-title":"Fabry\u2019s disease","volume":"372","author":"YA Zarate","year":"2008","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","article-title":"Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry","volume":"93","author":"WR Wilcox","year":"2008","journal-title":"Mol Genet Metab"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females","volume":"38","author":"KD MacDermot","year":"2001","journal-title":"J Med Genet"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Maier EM, Osterrieder S, Whybra C, Ries M, Gal A, <etal>et al<\/etal>.. (2006) Disease manifestations and X inactivation in heterozygous females with Fabry disease. Acta Paediatr Suppl 95: 30\u201338.","DOI":"10.1080\/08035320600618809"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/GIM.0b013e31802d8321","article-title":"Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life","volume":"9","author":"RY Wang","year":"2007","journal-title":"Genet Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s10897-008-9179-7","article-title":"Disease rarity, carrier status, and gender: a triple disadvantage for women with Fabry disease","volume":"17","author":"AL Gibas","year":"2008","journal-title":"J Genet Couns"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1136\/jmg.2005.036327","article-title":"Natural history of Fabry disease in females in the Fabry Outcome Survey","volume":"43","author":"PB Deegan","year":"2006","journal-title":"J Med Genet"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"34","author":"A Mehta","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1146\/annurev-med-050311-163340","article-title":"Podocyte biology and pathogenesis of kidney disease","volume":"64","author":"J Reiser","year":"2013","journal-title":"Annu Rev Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/ki.2010.484","article-title":"Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease","volume":"79","author":"B Najafian","year":"2011","journal-title":"Kidney Int"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","article-title":"Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy","volume":"62","author":"BL Thurberg","year":"2002","journal-title":"Kidney Int"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease","volume":"18","author":"DP Germain","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1523-1755.2005.67097.x","article-title":"Pathways to nephron loss starting from glomerular diseases-insights from animal models","volume":"67","author":"W Kriz","year":"2005","journal-title":"Kidney Int"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1681\/ASN.2010090963","article-title":"Podocyte injury damages other podocytes","volume":"22","author":"T Matsusaka","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1681\/ASN.2012030316","article-title":"Agalsidase benefits renal histology in young patients with Fabry disease","volume":"24","author":"C Tondel","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/ndt\/gfs526","article-title":"Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice","volume":"28","author":"W Terryn","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00467-012-2222-9","article-title":"Renal complications of Fabry disease in children","volume":"28","author":"B Najafian","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Warnock DG, Mauer M (2014) Fabry Disease: Dose Matters. J Am Soc Nephrol.","DOI":"10.1681\/ASN.2013121322"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"F333","DOI":"10.1152\/ajprenal.00478.2012","article-title":"The podocyte\u2019s response to stress: the enigma of foot process effacement","volume":"304","author":"W Kriz","year":"2013","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000327075","article-title":"Quantitating glomerular endothelial fenestration: an unbiased stereological approach","volume":"33","author":"B Najafian","year":"2011","journal-title":"Am J Nephrol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.2337\/db07-0019","article-title":"Podocyte detachment and reduced glomerular capillary endothelial fenestration in human type 1 diabetic nephropathy","volume":"56","author":"M Toyoda","year":"2007","journal-title":"Diabetes"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1038\/ki.2008.413","article-title":"Podocyte foot process effacement as a diagnostic tool in focal segmental glomerulosclerosis","volume":"74","author":"JK Deegens","year":"2008","journal-title":"Kidney Int"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1046\/j.1523-1755.1999.00407.x","article-title":"Complement-mediated injury reversibly disrupts glomerular epithelial cell actin microfilaments and focal adhesions","volume":"55","author":"PS Topham","year":"1999","journal-title":"Kidney Int"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/ki.1978.32","article-title":"Early renal changes in hemizygous and heterozygous patients with Fabry\u2019s disease","volume":"13","author":"MC Gubler","year":"1978","journal-title":"Kidney Int"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00428-008-0653-2","article-title":"Kidney biopsy findings in heterozygous Fabry disease females with early nephropathy","volume":"453","author":"C Valbuena","year":"2008","journal-title":"Virchows Arch"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.2337\/diabetes.54.6.1626","article-title":"From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy","volume":"54","author":"G Wolf","year":"2005","journal-title":"Diabetes"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1750-1172-5-14","article-title":"Expression of the disease on female carriers of X-linked lysosomal disorders: a brief review","volume":"5","author":"LL Pinto","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1001\/jama.295.12.1428","article-title":"The role of X inactivation and cellular mosaicism in women\u2019s health and sex-specific diseases","volume":"295","author":"BR Migeon","year":"2006","journal-title":"JAMA"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"JM Aerts","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1399-0004.2004.00219.x","article-title":"The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy","volume":"65","author":"C Whybra","year":"2004","journal-title":"Clin Genet"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00109-005-0656-2","article-title":"Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the alpha-galactosidase A gene in the Czech and Slovak population","volume":"83","author":"R Dobrovolny","year":"2005","journal-title":"J Mol Med (Berl)"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.gene.2012.06.013","article-title":"X-inactivation in Fabry disease","volume":"505","author":"D Elstein","year":"2012","journal-title":"Gene"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/ndt\/gfr420","article-title":"Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation","volume":"27","author":"DG Warnock","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"ref34","unstructured":"(2013) The Human Gene Mutation Database at the Institute of Medical Genetics in Cardiff."},{"key":"ref35","first-page":"227","article-title":"Fabry disease: twenty-two novel mutations in the alpha-galactosidase A gene and genotype\/phenotype correlations in severely and mildly affected hemizygotes and heterozygotes","volume":"48","author":"P Ashton-Prolla","year":"2000","journal-title":"J Investig Med"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/BF03401671","article-title":"Fabry disease: thirty-five mutations in the alpha-galactosidase A gene in patients with classic and variant phenotypes","volume":"3","author":"CM Eng","year":"1997","journal-title":"Mol Med"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"c33","DOI":"10.1159\/000085709","article-title":"Fabry disease in patients with end-stage renal failure: the potential benefits of screening","volume":"101","author":"S Bekri","year":"2005","journal-title":"Nephron Clin Pract"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000350147","article-title":"A Missense Mutation of the alpha-Galactosidase A Gene in a Chinese Family of Fabry Disease with Renal Failure","volume":"37","author":"C Wang","year":"2013","journal-title":"Kidney Blood Press Res"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0112188","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T08:30:19Z","timestamp":1589013019000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0112188"}},"subtitle":[],"editor":[{"given":"Stuart E.","family":"Dryer","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,11,11]]},"references-count":38,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2014,11,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0112188","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,11]]}}}